DRTS
Alpha Tau Medical Ltd.
$13.23
▲ +17.91%$13.23▲ +343.96%
over 1Y
L $2.90H $13.23
Today+17.9%
1W+18.4%
1M+48.2%
3M+91.2%
YTD+173.9%
1Y+344.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.37x).
Return on equity -55.3% · latest
Alpha Tau Medical Ltd. shows limited reported revenue, and -55.3% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.37x).
Is DRTS a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~13.23
- Short call 14 @ ~1.94 est
debit $1,129max +$271max −$1,128BE 11.29
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.8M | -$32.1M | -$35.7M | -$36.0M | -$42.3M |
| Net income | -$27.3M | -$33.8M | -$29.2M | -$31.8M | -$42.6M |
| Diluted EPS | -$0.67 | -$0.53 | -$0.42 | -$0.45 | -$0.53 |
| Net margin | — | — | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.19B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-3.6%
FCF yield-2.7%
Quality & risk
ROIC (est.)-40.6%
Free cash flow-$32.8M
Total debt$5.25M
Net cash$6.95M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+25.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗4Period ending 2026-07-012026-07-02open ↗144Filing2026-07-02open ↗4Period ending 2026-06-302026-07-01open ↗144Filing2026-06-30open ↗4Period ending 2026-06-252026-06-26open ↗144Filing2026-06-26open ↗6-KPeriod ending 2026-06-252026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗6-KPeriod ending 2026-06-232026-06-23open ↗144Filing2026-06-23open ↗6-KPeriod ending 2026-06-112026-06-11open ↗4Period ending 2026-06-032026-06-04open ↗
Frequently asked
- Is Alpha Tau Medical Ltd. (DRTS) a buy?
- DRTS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.37x).
- What is Alpha Tau Medical Ltd.'s quality score?
- DRTS scores 47.56249999999999/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001871321, latest 4 filed 2026-07-02) · EODHD · as of 7/4/2026, 10:39:34 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:39 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.